



Improving Medication Outcomes and Reducing Medical Costs

Learn more about personalizing medication regimens for ACO Members

Demonstrated savings and documented ROI, in the same year

Tackling polypharmacy and preventable adverse drug events (ADEs)

GalenusRx optimizes medication regimens and reduces ADEs, including premature death, by identifying patients with inappropriate and unoptimized medication regimens. GalenusRx has developed the only system in the world that uses deep drug disposition science to assess simultaneous multi-drug, multi-drug-disease and multi-drug-gene interactions, while providing Lifesaving Insights™ demonstrated to improve outcomes with documented ROI.



Enhance ACO member engagement and quality of life.

With our Actionable PolyPharmacy Regimen Assessment Index for Safety and Equity, APPRAISE, an inclusive drug safety solution. GalenusRx improves medication-related experiences for patients with polypharmacy.

Our solutions are supported by peer-reviewed publications, sponsored by governmental and private organizations and conducted by the Founders for over 25 years.

“Our solutions are especially beneficial for populations that are often overlooked such as women and the elderly.”

Veronique Michaud, BPharm, Msc, PhD,
President, GalenusRx, Inc.

GalenusRx APPRAISE technology identifies members with high concern for ADEs, and those who will benefit the most from a Pharmacogenomic (PGx) test, included in our service, based on levels of evidence and clinical impact.

REACH OUT TODAY AND LEARN HOW YOU CAN PARTNER WITH US.

Peter Panageas

Chief Commerical Officer
PPanageas@GalenusRx.com
856.630.8613

Orsula V. Knowlton, PharmD, MBA

Co-Founder, Chief Strategy and Innovation Officer
OVKnowlton@GalenusRx.com
215.680.8983

Visit our website to learn more
GALENUSRX.COM.

For more information →

Opportunity for New Clients

Partner with GalenusRX to improve health by delivering personalized and precision medication regimens.

STEPS

1 ACO Provides Data

- Sign mutual NDA and BAA
- Provide member medication data for Part B and D drugs, e.g., CCLF File, PBM data, etc.
- Establish baseline benchmark data

2 GalenusRx APPRAISAL

- Receive ACO data
- Identify the APPRAISE savings cut point
- For every 10,000 members, an estimated 2% or \$1.8MM is estimated; a 3:1 or greater ROI (pre- shared savings and quality score)

3 Partnership Establishment

- Review of GalenusRx proposed pricing model
- Lifesaving Insights is a subscription PMPM
- Includes APPRAISE level of concern, medication reconciliation, initial and follow-up, member/clinical pharmacist consultation for optimal results

4 Implementation & Engagement

- Identify implementation process for optimal member engagement
- Begin member medication regimen optimization


5 Quarterly Business Review

- Ongoing review of results to assure savings

GalenusRx: Delivering Lifesaving Insights™



1-to-1 drug interaction software is more than five decades obsolete, does not address polypharmacy complexity



Simultaneous multi-drug analysis using pharmacokinetics (DMEs and drug-transporters), pharmacodynamics and chronopharmacology addresses polypharmacy complexity

REACH OUT TODAY AND LEARN HOW YOU CAN PARTNER WITH US.

Peter Panageas

Chief Commerical Officer
PPanageas@GalenusRx.com
856.630.8613

Orsula V. Knowlton, PharmD, MBA

Co-Founder, Chief Strategy and Innovation Officer
OVKnowlton@GalenusRx.com
215.680.8983



Advanced technology, testing capabilities, & professional expertise bridge the multi-drug interaction gap for members and their healthcare professionals.



GalenusRx saves time and money for clients by embedding GalenusRx services into existing and new offerings.



Partnerships help scale access to GalenusRx Lifesaving Insights & clinical expertise.



GalenusRx Product Design and AI help pharmacists review clinical pharmacy information and test results faster than ever reducing costs and and improving efficiency.